Joint Thoracic Oncology Research Unit of LYon: Lung cancerS DatabaSE (ULYSSE)
NCT ID: NCT05267041
Last Updated: 2025-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
4000 participants
INTERVENTIONAL
2022-05-05
2042-05-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Initiative in LYon for Lung cAncer Screening Development - Prevalence Study
NCT04240418
Comprehensive Geriatric Assessment and Complications Following Lung Resection for Lung Cancer
NCT01956331
A Clinico-biological Database of Lung Cancers
NCT03387865
Determinants of Intensity of Care of Lung Cancer Patients With Organ Failure
NCT01999621
Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE
NCT05649046
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort of Adults with lung cancer
Patients newly diagnosed with lung cancer.
Blood sample
One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer
Questionnaire
to collect data not reported in the patient's medical file, such as passive smoking, family history of cancer, and attempts to quit smoking.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sample
One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer
Questionnaire
to collect data not reported in the patient's medical file, such as passive smoking, family history of cancer, and attempts to quit smoking.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis can be done:
* By cytology or pathologic assessment
* Or by multidisciplinary team meeting decision:
* Irradiation without morpho-metabolic sampling
* Treatment without sampling based on non-invasive molecular data
Exclusion Criteria
For optional blood sampling :
* \< 30 kg for blood collection
* No blood sampling schedule for care
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
69HCL21_1175
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.